Details for Patent: 6,113,942
✉ Email this page to a colleague
Title: | Pharmaceutical composition for piperidinoalkanol compounds |
Abstract: | The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient. |
Inventor(s): | Ortyl; Thomas T. (Overland Park, KS), Skultety; Paul F. (Leawood, KS), Mitchell; Kristen C. (Lee's Summit, MO), Phadke; Deepak S. (Olathe, KS), Attarchi; Faraneh (Kansas City, MO), Pierce; Marguerite L. (Fairway, KS), Schoeneman; Aaron W. (Lee's Summit, MO), Schnitz; Joseph M. (Kansas City, MO) |
Assignee: | Aventis Pharmaceuticals Inc. (Bridgewater, NJ) |
Filing Date: | Sep 21, 1998 |
Application Number: | 09/157,841 |
Claims: | 1. A pharmaceutical composition in solid unit dosage form comprising: a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR10## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) inert ingredients comprising croscarmellose sodium, lactose, microcrystalline cellulose, pregelatinized starch and gelatin. 2. A pharmaceutical composition in solid dosage form comprising: a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR11## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) inert ingredients comprising croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate. 3. A pharmaceutical composition in solid unit dosage form comprising: a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR12## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) inert ingredients comprising croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate. 4. The pharmaceutical composition in solid unit dosage form according to either of claims 1, 2, or 3 wherein the piperidinoalkanol compound is present in an amount of about 5 mg to about 180 mg. 5. The pharmaceutical composition in solid unit dosage form according to either of claims 1, 2, or 3 wherein the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid hydrochloride has a particle surface area of greater than about 1.0 m.sup.2 /g. |